Background and Purpose-Significance and management of blood pressure (BP) changes in acute stroke care are unclear.
I
n the acute phase of stroke, up to three quarters of patients experience high blood pressure (BP), a phenomenon yet understood incompletely. 1, 2 Guidelines recommend tolerating a BP up to 220/120 mm Hg, 185/110 mm Hg, and 180/105 mm Hg in patients in general, before, and after administering intravenous thrombolysis (IVT) because of the most feared complication symptomatic intracerebral hemorrhage (SICH). 3 Most observational studies found an association between higher admission systolic BP (BP sys ) and worse outcome describing a distinct U-shaped admission BP sys relation. Thereby, a range of 141 to 150 mmHg BP sys yielded best functional outcome at 90 days after stroke. [4] [5] [6] [7] [8] Even so, clinical trials investigating active BP lowering in acute ischemic stroke have not shown an advantage from BP intervention neither for safety nor for functional outcome.
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positive association of BP lowering and functional outcome irrespective of whether the patient received IVT or not. 13 About bleeding complications after IVT, reports are conflicting where some reported an association between post-thrombolysis BP elevation and hemorrhagic transformation, but others did not. [14] [15] [16] The randomized ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study, BP arm) investigating superior efficacy and lower risk of any intracerebral hemorrhage of early intensive lowering of BP (systolic target 130-140 mm Hg) versus BP control as recommended in guidelines (systolic target <180 mm Hg) is ongoing, and results are anticipated in 2018. 17 For several years, stroke neurologists have focused on not only standard BP parameters but also BP variability (BPV, for review Manning et al 18 ). For the short-term BPV, higher BPV was shown to increase the rates of SICH, death, and poor outcome after stroke. [19] [20] [21] Recently, a post hoc analysis of 2 clinical trials investigating BPV (assessed as SD) showed no significant association with 2-week functional dependency after stroke and in-hospital mortality. 22 More recently, higher BPV within 24 hours after stroke was demonstrated to be associated with poor prognosis after IVT. 13, 23 BP management in acute ischemic stroke is relevant for clinical practice, but individual strategies are not yet established. Here, we determined the influence of BP and BPV during the first 24 hours on short-and long-term outcomes in a large international cohort of patients who received IVT, reflecting the status quo of BP management.
Methods

Study Setting
Acute ischemic stroke patients treated with IVT (Actilyse; Boehringer Ingelheim, Germany) and recorded in the Safe Implementation of Treatment in Stroke (SITS) international registry between 2002 and 2013 (https://sitsinternational.org) were considered for analysis (n=58 294). Only patients with complete baseline, imaging, outcome, and BP measurements (n=28.976; 49.7%) comprised the current study sample. 24 The SITS registry is an ongoing large international registry prospectively enrolling at 1422 centers in 70 countries. Stroke centers contributing to SITS assessed stroke severity with the National Institutes of Health Stroke Scale (NIHSS) score. For full details of methodology including issues of management about patients data including source data and identification, the reader is kindly referred to previously published work.
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Definition of BPV
BP values in SITS were documented at least at 3 time pointspre-treatment, at 2 hours, and at 24 hours after IVT. At each time point, there was only 1 BP reading documented. Of these 3 systolic BP values, BPV was calculated. As primary measure of variability, we choose successive variation (SV) for analysis of BPV (BPV SV ) because it addresses the time sequence in measurements more appropriately than other measures. 25 SV was calculated as square root of average squared difference between 2 successive BP measurements according to following equation:
Outcome Definitions
Functional outcome at 3 months was measured by the modified Rankin Scale (mRS)-it ranges from 0 to 6. If raters judged 0 or 1, excellent functional outcome, and if 0 to 2, good or functional independent outcome was concluded.
The primary aim of this study was to investigate the relationship of the influence of BPV SV and pre-treatment BP sys on excellent and good outcomes after 3 months. In addition, an ordinal analysis of the 3-month mRS was performed. Recanalization leads to an improvement in early neurological outcome and may likely be associated with a drop in BP. [26] [27] [28] Because the overall number with documented cases of recanalization was low (<20%) and this was not the primary aim of the study, we chose 2 outcome definitions of early neurological improvement (ENI) within 24 hours as a proxy for presumed vessel patency: (1) ENI 20% defined as an improvement of ≥20% on the NIHSS because this definition was previously demonstrated to be the best predictor of functional 3-month outcome and (2) ENI 8 defined as an improvement of ≥8 points on the NIHSS. [29] [30] [31] Safety measures included the occurrence of SICH after IVT according to SITS and ECASS-2 definitions (ECASS-2 [European Cooperative Acute Stroke Study 2]; in the online-only Data Supplement).
Ethics
Patients within SITS received thrombolysis as standard of care. This was a retrospective analysis. Therefore, new ethics review was not necessary for data analysis because ethical approvals had been obtained in countries where they are required. In other countries, SITS was approved as an anonymized register without need for ethical approval.
Statistical Analysis
For information how the sample was preprocessed-that is, imputation strategies, listwise deletion, and coarsened exact matchingwe kindly refer the reader to the Methods in the online-only Data Supplement.
Normally distributed data are presented as mean and SD, non-normally distributed data as median and interquartile range. For categorical variables, counts and percentages are given. Univariate statistics used Student t test, Mann-Whitney U test, or χ 2 where appropriate. Association between BPV SV and 3-month outcome was estimated by binomial and ordinal logistic regression. In multivariable regression analysis, adjustments were made for age, sex, NIHSS, BP sys , history of arterial hypertension, history of diabetes mellitus, history of hypercholesterolemia, current smoking, previous stroke, history of atrial fibrillation (AF), and history of coronary heart failure. We allowed for interactions of BP sys and BPV SV on a multiplicative scale and compared the model including the interaction with the main model by a likelihood ratio test. 32 For main predictors, a 2-sided P<0.01 and for interactions terms, a P<0.05 was considered as statistically significant. For odds ratios and 95% confidence intervals to reflect meaningful values (because of the high number of patients), reported odds ratios for continuous variables BPV SV and BP sys reflect a change from the 25th to the 75th percentile. Graphical presentation of the interaction, BP sys ×BPV SV , is on the scale of predicted probabilities using example values of BPV SV 
Analysis of BPV
Sensitivity Analysis
Patients who had AF usually present with higher variability in BP readings. 33 Therefore, we excluded patients who had known history of AF at presentation, testing only non-AF patients for sensitivity analysis. This sensitivity analysis should therefore exclude the contribution of the AF population to BPV although we had no information on newly diagnosed AF in this data set.
Results
Patients Characteristics According to BPV SV
Of 28 976 patients in the entire cohort, 16 434 patients remained after preprocessing. Table 1 shows patients baseline characteristics in the entire cohort and the matched cohort. BPV SV was categorized into groups (<15, 15-29.9, 30-45, and >45) for presentation purposes only reflecting 60.2%, 32.4%, 6.0%, and 1.4% of the matched cohort, respectively.
Successive BPV
Associations between BPV SV and other covariates were found. Best associative strength was found in a positive, moderate correlation of pre-treatment systolic BP (r=0.267; P<0.000001) and BPV SV . Furthermore, longer stroke onset to treatment times (r=0.029; P=0.000001) and higher age (r=0.101; P<0.000001) were weakly correlated to higher BPV SV , whereas correlation between BPV SV and NIHSS (r=−0.013; P=0.024) was hardly evident. Patients experiencing higher BPV SV were women and had history of hypertension, diabetes mellitus, hypercholesterolemia, AF, smoking, and prior stroke (all P<0.01). No association was found for patients with history of heart failure (P=0.787).
To further determine which baseline factor would explain most of the variance of BPV SV , linear multivariable regression analysis demonstrated pre-treatment systolic BP to be most 
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influential (5.55% explained variance), followed by age (1.18% explained variance). Interestingly, patients with history of hypertension were only marginally predictive for higher BPV SV (0.2% explained variance). All other variables also explained <1% variance leaving 92% of the variance in BPV unexplained ( Figure 1 ).
Outcome Analysis According to BPV SV
Early Neurological Improvement About short-term outcome, univariate analysis of BPV SV was not significantly associated with ENI 20% (P=0.428) and ENI 8 (P=0.394). Adjustment with relevant confounders in multivariable analysis did not change this result (Table 2) .
Three-Month Outcome
Excellent outcome was not significantly associated with BPV SV by means of univariate (P=0.346) and multivariable (Table 2) adjustments. Functional independency was less likely in patients with higher BPV SV by means of univariate (P=0.021) and multivariable regression (Table 2) analyses.
A shift to the next higher (worse) mRS category (categorical shift) was more likely in patients with higher BPV SV in multivariable regression analysis (Table 2) .
Mortality within 90 days after stroke was more likely in patients who experienced higher BPV SV (univariable, P=0.004; multivariable, Table 2 ).
Symptomatic Intracerebral Hemorrhage
In terms of safety, BPV SV was associated with the presence of SICH SITS (P=0.0001) and SICH ECASS (P=0.0017). Adjustment in multivariable analysis reinforced these results irrespective of the bleeding definition used (Table 2) .
Outcome Analysis According to Pre-Treatment BPV sys
Higher BPV sys was significantly associated with lower odds ratios for ENI, lower rates of favorable outcome at 3 months, and higher risk of SICH in multivariable analysis. No association with mortality was found ( Table 2) .
BPV SV and Pre-Treatment BP sys Interaction (BPV SV -by-BP sys )
Determining outcome across the mRS at different levels of BPV SV and across the range of BP sys revealed an X-shaped relationship ( Figure 2 ): BPV SV -by-BP sys interaction was found for outcomes of ENI 20% but not for ENI 8 for excellent and good functional outcome as well as for the shift analysis of the mRS. This relationship was not obvious for mortality and safety (Table 3) .
Sensitivity Analysis of BPV SV -by-BP sys Interaction in Patients Presenting With No History of AF
Outcome analysis in non-AF patients on BP sys and BPV SV and their interaction was largely unchanged and is shown in Tables  I and II in 
Discussion
In this study with a large cohort of ischemic stroke patients treated with IVT, we highlight the prognostic significance of successive BPV SV for functional outcome after stroke and especially for safety. A novel finding in our study is the better prediction of short-and long-term functional outcomes when considering the reciprocal interaction of pre-treatment BP (BP sys high, medium, or low) and the course of BP 24-hour post-thrombolysis (accounted by BPV SV ).
BPV in our study was associated with several definitions of functional outcome and safety. Importantly, these results were independent of BP sys (a well-known predictor of safety 15, 16 and functional outcome after stroke 4, 6, 8, 13, 34 ). A post hoc analysis from IST-3 (The Third International Stroke Trial) reported an association of higher BPV with adverse events, the occurrence of SICH and poor 6-month outcome. 13 Our results may complement those in so far that we found short-term BPV to be of significance for safety (SICH) and several long-term outcome definitions. About short-term outcome (2-week outcome and in-hospital outcome), 2 most recent studies did not find any importance of BPV in outcome prediction. 22, 23 Our results support these studies for the most part because we found no clear association of BPV with early neurological improvement too (ENI 20 and ENI 8 ).
The overall comparability of those studies with ours is narrow because of smaller sample sizes, different acquisition of BP intervals, and various definitions of BPV and outcomes.
Pursuing the notion of both BP characteristics (BP sys and BPV SV ) being relevant to several issues, we put both in context by analyzing whether patients with a particular pre-treatment BP would yield different functional outcomes with various degrees of BPV (Figure 2A and 2B) . For patients who presented with normal BP sys , neither high nor low BPV SV seemed to influence the outcome in some way or other. However, patients presenting with low BP sys seemed to benefit from low BPV SV . Equally did patients with high pre-treatment BP sys and high BPV SV . This combination (high BP sys +high BPV SV ) seems, for example, when physicians actively intervene on high BP sys but may also be attributed to the natural BP course after stroke-the trend of BP to decline over time. In this regard, the post hoc analysis of IST-3 suggested similarly a good outcome at 6 months after stroke when BP lowering was more intense during the first 24 hours, 13 whereas other studies did not. [9] [10] [11] [12] 35 In patients in whom pre-treatment BP sys is within the normal range, physicians usually restrain active elevation of BP (resulting in low BPV SV ). The combination of high BP sys and low BPV SV seems unfavorable, most probably because BP sys remains too high because of lack of extrinsic or intrinsic modulation or because of insufficient response to possible interventions. An equally unfavorable combination seems to be low BP sys and high BPV SV that might be explainable by exceedingly BP lowering leading to cerebral hypoperfusion or vice versa unstable conditions and the need for interventional elevation of BP.
Overall, these results indirectly indicate that patients may benefit from BP management that is personalized. This hypothesis could (at least partially) explain inconsistencies in several observational studies on BP lowering, where some suggested much lower absolute BP sys values to be favorable (range between 140 and 150 mmHg). 4, 6, 8 In contrast, several post hoc analyses of randomized clinical trials reported no advantage. [9] [10] [11] [12] 35 The BP arm of the ENCHANTED trial is still ongoing, possibly the results will offer insights about the importance of BP lowering in thrombolyzed patients. 17 Certainly, BP management in the acute phase of stroke should include aspects of the presence of penumbra, presence of vessel occlusion, collateral flow, revascularization status, Adjusted for age, sex, baseline NIHSS, history of arterial hypertension, history of diabetes mellitus, history of hypercholesterolemia, history of smoking, history of atrial fibrillation, history of coronary heart failure, and prior stroke. ECASS-2 indicates European Cooperative Acute Stroke Study 2; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and SITS, Safe Implementation of Treatment in Stroke.
*Indicating a 12-point change in blood pressure variability (=change from 25th percentile to 75th percentile). †Indicating a 25-point change in systolic blood pressure (=change from 25th percentile to 75th percentile). 
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and stroke cause. 36 Although our analysis falls short to address these individual aspects because of its retrospective design, we interpret our findings a step toward a better understanding of BP and BPV in acute stroke.
The authors may also point toward a better understanding of variability as BP characteristic (see Manning Stroke 2015 for review 18 ). In observational studies, where BP management is not actively monitored, it is unclear what we exactly measure when we measure BPV. BPV is under the influence of numerous extrinsic (administered and preexisting medication, arrhythmia requiring β-blocker, vegetative and emotional stressors, and positional [eg, lying versus upright] and continuous recording versus manual measurement) and intrinsic (arterial hypertension, fluid balance, stroke subtype, recanalization, and autonomic regulation or dysregulation) factors. 37, 38 Even so, attempts to explain BPV in the multivariable analysis by all available patients baseline characteristics left 92% variance unexplained in our study.
Interestingly, BP sys was the strongest predictor for BPV. As for some definitions of BPV, this could easily be explainable because pre-treatment BP sys influences, for example, SD to a certain extent (depending on the number of available BP readings). Therefore, we considered a similar type of influence for the variability measure chosen in this study (successive BP variability). In the SITS International Thrombolysis registry, BP is documented at only 3 time points. This is because to minimize the workload of the investigator because the SITS IVT protocol has ≈200 other variables. The individual centers were not required to standardize their protocol when measuring BP-both facts that might lead to bias in interpretation of BP and BPV. In routine clinical practice, BP is measured at least hourly after IVT up until follow-up imaging, but unfortunately these additional data are not available in the SITS registry. However, as shown in the online-only Data Supplement, we demonstrate that the variability formula of BPV SV is less prone to single values. 25 This also improves plausibility that our finding of BP sys -by-BPV SV interaction is not explainable as a by-product of the chosen BPV definition.
Besides the main limitation of uncontrolled data and retrospective analysis, our study has additional limitations. Although we demonstrated no influence of NIHSS or other baseline factors on BPV in linear regression, BPV may still be an epiphenomenon of clinical parameters, for example, severity of stroke, lesion growth (as demonstrated by DelgadoMederos et al 39 ) , or BP lowering interventions. We present an effect of the interaction between BP and BPV for the whole cohort and for those patients without AF, but most likely, there were subgroups of patients (different stroke causes, presence of penumbra, vessel occlusion, recanalization status, and collateral flow) for whom this interaction might be more or less relevant. None of these factors was investigated in a wellstructured way with respect to BPV.
Because of the retrospective design of this study, we were not able to control neither for a single nor much less for all of those variables. Only about a half of all patients registered in SITS were further analyzed, and after preprocessing, only 16 434 patients (28%) remained; this is an important limitation of the study. Matching may reduce overall degree of bias; however, it has to be stressed that control of unobserved variables-as in randomized trials-is not possible.
Despite these limitations, we interpret our findings as novel and significant with implications for patient care and future studies. The main strength of our study is that it comprises by far the largest cohort of IVT-treated patients in whom this analysis has been completed.
Conclusions
BP variability during 24 hours after thrombolysis is of significant but currently under investigated relevance for stroke outcome. Putting the course of BP 24 hours post-thrombolysis in relation to its pre-treatment value significantly improved the prediction of specific short-and long-term outcomes of stroke in this study. Thus, future clinical trials should carefully consider both-pre-treatment BP and its variability over time. BP indicates blood pressure; BPV, blood pressure variability; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and SITS, Safe Implementation of Treatment in Stroke *Multivariable regression analysis including multiplicative interaction of pretreatment systolic BP and successive BPV adjusted for confounders of age, sex, baseline NIHSS, history of arterial hypertension, history of diabetes mellitus, history of hypercholesterolemia, history of smoking, history of atrial fibrillation, history of coronary heart failure, and prior stroke.
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